Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

relating to the offering was filed with the SEC on October 6, 2009. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX fails to submit an ANX-530 NDA, whether by December 31, 2009 or at all; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the submiss
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... announced the appointments of Dr. Ashraf Hanna , ... M.S., to its Board of Directors. Dr. Hanna is ... at Genentech and Chief Financial Officer for the Genentech ... President and Global Head of Business Development and Licensing ...
(Date:9/18/2014)... 18, 2014 Relmada Therapeutics, Inc., (OTCQB: RLMD), ... of chronic pain, announced today that it has appointed ... of  Senior Director of Clinical Development. During ... established and led successful global clinical operations teams, in ... facilitate the clinical development of numerous therapeutics and diagnostics ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
(Date:9/18/2014)... It’s been just a few short weeks since ... splint to website visitors, but already the response has been ... delighted. It is perfect and I find it sooo much ... YOU FOR LISTENING!!!" Another user compared the original design ... to slip to the end of my toe. Now that ...
(Date:9/18/2014)... LAKE, Wis. (PRWEB) September 18, 2014 It ... and engage in health and wellness. Once again, Evensong ... in Spa Week by offering three services at a special ... Evensong Spa, managed by Marcus Hotels & Resorts , ... a national event encouraging Americans to embrace health and wellness ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... In 2003, the government ... Barrio Adentro), which it hoped would increase ... Section 6.1.3.). In 2009, it invested VEF28 ... of Pharmaceutical Elaborations (Servicio Autónomo de Elaboraciones ... at a cheaper rate than private pharmaceutical ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Qualis Health, ... has published a white paper, “Advancing Primary Care ... Health Information Technology.” , Authors Jeff Hummel, MD, ... provide guidance to organizations engaged in the work of ... health IT can bolster PCMH objectives, such as generating ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... Reduce Stiffness for Better Health with,Innovative ,Sleep and ... FORT LAUDERDALE, Fla., Jan. 9 Contour ... people implement an,ergonomic makeover into their life for ... well being. By aligning the body, relieving,pressure points ...
... Makes Available New Daily Dosing Option for the Treatment ... and Company,(NYSE: LLY ) announced today that the ... for once daily use (2.5 mg and,5 mg), an ... dysfunction,(ED). When Cialis for once daily use is taken ...
... private equity, public offering, ... Irell represents leading clients in gaming, green tech, ... construction, LOS ANGELES, Jan. 8 Irell & Manella ... corporate deals,valued at more than $7 billion., The firm ...
... years, The Leukemia &,Lymphoma Society has organized "Team ... achieve personal goals and most of all, raised,over ... video from The Leukemia & Lymphoma Society at:, ... In Training" helps,individuals prepare for a full marathon ...
... Red Cross,announced today that J. Chris Hrouda has ... for the organization,s Biomedical Services., Hrouda will ... Each year the American Red Cross collects approximately ... million blood products to,patients at approximately 3,000 hospitals ...
... 8 Conseco, Inc. (NYSE:,CNO) announced that Todd M. ... senior vice president and treasurer. He will report to ... Hacker joins Conseco from YRC Worldwide, where he was ... treasurer from,2004-2005. From 2005-2006, he was senior vice president, ...
Cached Medicine News:Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 2Health News:Irell & Manella Posts Strong Year for Corporate Transactions 3Health News:Irell & Manella Posts Strong Year for Corporate Transactions 4Health News:Irell & Manella Posts Strong Year for Corporate Transactions 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 6Health News:American Red Cross Announces New Leader for Biomedical Services 2
... The best lens available ... trabeculoplasty. One 62 mirror. ... image and laser beam ... be used on most ...
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
Medicine Products: